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Exercise training (ET) and secondary prevention measures in cardiovascular disease aim to stimulate early physical activity and to facilitate
recovery and improve health behaviours. ET has also been proposed for heart failure patients with a ventricular assist device (VAD), to help
recovery in the patient’s functional capacity. However, the existing evidence in support of ET in these patients remains limited.
After a review of current knowledge on the causes of the persistence of limitation in exercise capacity in VAD recipients, and concerning the
benefit of ET in VAD patients, the Heart Failure Association of the European Society of Cardiology has developed the present document
to provide practical advice on implementing ET. This includes appropriate screening to avoid complications and then starting with early
mobilisation, ET prescription is individualised to meet the patient’s needs. Finally, gaps in our knowledge are discussed.
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Introduction
Around 5–25% of heart failure (HF) patients reach an end-stage
condition, despite the use of optimal medical therapy.1,2 At this
stage three options are currently indicated: ventricular assist
device (VAD) implantation, heart transplantation (HT), or pallia-
tive care.3,4 In the modern setting of an increasing HF population
and because of the scarcity of heart donors, the VAD option is
emerging as a strategy for bridge to HT or as a destination therapy
(DT) for those ineligible for HT3: a small number of VAD patients
may have sufficient recovery of myocardial function (bridge to
recovery) to allow device to be explanted.4 Although functional
capacity usually improves compared to the pre-implantation
status, VAD recipients still experience an impaired exercise
capacity.5,6
Exercise training (ET) is highly recommended in HF because of its
beneficial effects on functional capacity and prognosis.3,7–10 More
recently, it has been proposed also in VAD recipients.11,12 This
latter strategy, however, has not been uniformly implemented, as
shown by the European Exercise Training Survey,13 a fact that has
been attributed to lack of knowledge, low prioritization, variability
in official recommendations, heterogeneity of the surgical interven-
tion (simple or shared device implantation, combined valve surgery,
linked with ventricular ablation), indication (INTERMACS ranking),
or simply because the patients were considered too severely frail
(such as very elderly HF patients).
Based on the current consistent, but still limited evidence
supporting the safety and the benefit of early mobilisation (EM) and
ET in the VAD population, the Heart Failure Association (HFA) of
the European Society of Cardiology has developed this document
with the aim of promoting the implementation of exercise in VAD
recipients in clinical practice. First, the current knowledge on the
origin of limitations in exercise capacity and the available evidence
concerning the benefit of ET in VAD recipients are reviewed,
thereafter advice on the optimal modalities to implement ET in
clinical practice are presented and, finally, the gaps in knowledge
are discussed.
Exercise capacity in ventricular
assist device recipients
The transition from rest to exercise induces cardiovascular adjust-
ments to allow adequate tissue perfusion as well as increased
peripheral oxygen extraction. The normal physiologic response
to exercise is characterised by increased heart rate (HR) and car-
diac contraction force at a given left ventricular (LV) pressure,
leading to higher cardiac output (CO), through activation of the
sympathetic nervous system. During maximal exercise, CO nor-
mally increases four- to six-fold, shifting the Frank–Starling curve
to the left and upward, associated with peripheral vasodilatation.14
Although age, sex, fitness, inherited factors and the presence of
congenital cardiovascular abnormalities may have some influence,
the ability to augment CO in response to the higher metabolic
demand is one of the key factors regulating the cardiovascular
response to exercise.14 ..
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.. This situation is markedly different in individuals with heart
disease, when coexistent demographic factors seem to be less
critical.14 Usually, HF patients are limited in their exercise capac-
ity by maladaptive changes in the cardiovascular, musculoskeletal,
and respiratory systems.15,16 In particular in response to stress,
advanced HF patients are unable to augment CO adequately due
to impaired myocardial contractility, with consequent multi-organ
under-perfusion, hypoxia and muscular inefficiency.17 Exercise lim-
itation and deconditioning favour a feedback negative loop.3
Cardiopulmonary exercise testing (CPET) is considered the gold
standard tool in assessing the physiologic response to exercise,3,18
and in identifying individuals in need of advanced therapies (e.g. HT
or VAD implantation).18 However, pre-implantation VAD patients
may be too ill to perform CPET4,5 and thus comparisons of
peak oxygen consumption (VO2) values post-implantation are
mostly lacking19,20 or show conflicting results.21–23 In fact, there
is evidence that, over longer implant periods (i.e. 2 years), recip-
ients can show an enhanced exercise performance,24,25 either
in terms of CPET parameters or 6min walking test (6MWT)
distances.6,19,25–28 In contrast, some patients may still exhibit sig-
nificant impairment in exercise capacity6 due to a variety of causes:
• Device characteristics (e.g. inability to increase CO during
exercise due to the absence of ramp function, unloading speed,
the presence of the operating console and the drive line).
• Cardiac abnormalities (e.g. native LV contribution, right ven-
tricular dysfunction, chronotropic incompetence).
• Co-morbidities (e.g. impaired pulmonary function, skeletal
myopathy, endothelial dysfunction, anaemia).
• Patient’s characteristics (i.e. age, gender, disease aetiology
and duration of disease, length of hospitalisation, physical
deconditioning, and frailty).
Left ventricular unloading is important during VAD support,5 and
as a result, device speed is adjusted accordingly. The pump flow is
determined by the pump motor activity, the rotational speed, and
the VAD characteristics;29 however, only approximate estimation
of CO is possible because of the unknown volume of orthograde
blood flow across the aortic valve, which is affected by residual LV
myocardial function and pre- and afterload conditions. Rotational
speed affects flow and exercise tolerance as well,30,31 and speed
increase affects exercise capacity and peak VO2.
32,33
After VAD implantation, the contribution of native ventricular
contractility is complex: at rest, the VAD provides most of the
CO, whereas, during exercise, a variable contribution of the native
heart to CO has been described depending on right and left ven-
tricular contractile reserve interplay.6,27,30 The role of HR seems
to be less important, because it does not affect LVAD flows,34
although chronotropic incompetence, at least during the early
phase of the post-implant period, has been witnessed.35 Right ven-
tricular (RV) dysfunction may significantly limit maximal CO dur-
ing exercise,33,36,37 but tricuspid annular plane systolic excursion,
a known marker of RV function, and RV diastolic dimension did
not correlate with symptom-limited exercise capacity.34 Possibly,
RV longitudinal strain, a less load-dependent index of RV func-
tion, might represent a much more pathophysiologically relevant
© 2018 The Authors
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contributor to exercise capacity in a VAD patient, from the right
side of the heart.
Finally the contribution of pulmonary function and peripheral
factors remain unclear,35–37 but a key role of the peripheral circu-
lation has been proposed. There is evidence that the improvement
in leg blood flow accounts for most, if not all, of the increase in CO
observed post-implantation of a continuous-flow VAD.35 Also an
increased venous return associated with reduced peripheral resis-
tance and increased cardiac contractility has been advocated.36
Exercise training may enhance the benefit on peripheral haemo-
dynamic factors induced by VAD implantation.
In conclusion, exercise adaptation of the VAD recipient is com-
plex to understand: most studies have been focused on one limiting
factor rather describing the integrated exercise response, there-
fore a complete description of exercise adjustment has not yet fully
been worked out. There is recent evidence of the multiple effects of
VAD during exercise, such as improvements in central (CO) and
peripheral haemodynamics (muscle blood flow and oxygenation)
but with a detrimental effect on pulmonary function (lung diffusion
deterioration with increased obstructive apnoea, likely due to an
increase of intra-thoracic fluids).38
Review of the evidence in favour
of exercise testing in ventricular
assist device patients
Limited but promising data are available concerning the safety
and efficacy of EM (7–10 days post-implant) and ET in VAD
recipients (Table 1).39–48 In 2011, Laoutaris et al.42 provided
the first evidence of the feasibility and efficacy of ET in patients
with either left ventricular (LVAD) or biventricular (BiVAD)
assist devices participating in a 10-week exercise program,
6.3± 4months post-implantation. ET improved functional capacity
(peak VO2, 6MWT), exertional ventilatory response (VE/VCO2
slope), and quality of life (QoL). Subsequently, Adamopoulos
et al.43 extended these findings, showing that long-term ET also
decreased N-terminal pro B-type natriuretic peptide (NT-proBNP)
and triggered myocardial growth factors involved in evolution sig-
nalling pathways, in both LVAD and BiVAD patients. A multi-model
long-term (18months) ET intervention increased the percentage
of predicted peak VO2 in LVAD recipients,
44 while a shorter
(8-week) ET, started early after implantation and on a small
population (14 patients), provided no benefit with respect to
the control group.45 In a retrospective analysis, Karapolat et al.46
observed that an 8-week ET programme improved peak VO2,
pulmonary function and QoL similarly in LVAD recipients, HF
or HT patients. Kerrigan et al.47 in a 2:1 randomisation trial
comparing usual care vs. ET (which included 18 aerobic exercise
sessions at 60–80% of HR reserve), showed that ET improved
exercise capacity (peak VO2 by 10%, treadmill time by 3.1min,
6MWT distance by 52.3m), QoL (Kansas City Cardiomyopathy
Questionnaire score by 14.4 points), and leg strength (17%). More
recently, Marko et al.48 confirmed the improvement in peak VO2
and muscle strength in patients with LVAD after ET. ..
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.. In conclusion, although the small study populations limit the
evidence regarding the role of ET in VAD recipients, all data
support the feasibility, safety, and potential for benefit.40
How to implement exercise
Based on the available data, the HFA Committees hereby presents
practical advice on the modality of exercise implementation in VAD
patients. However the reader should bear in mind that the follow-
ing are only general recommendations: the implementation in clin-
ical practice is conditioned by local expertise, individual recipient
factor (e.g. timing of referral, type of intervention delivered, mul-
tidisciplinary approach), characteristics of the VAD recipients (e.g.
combined vs. single surgical interventions, indications for implan-
tation, underlying clinical condition, co-morbidities), and available
national recommendations and facilities.
Preliminary step – clinical assessment
and health professionals’ education
Medical professionals may be hesitant to start mobilisation because
of the presence of the device in a still debilitated patient, and spe-
cific skills and expertise are required. Thus, health care providers
should be familiar not only with exercise physiology and the dif-
ferent exercise modalities but also with device functioning,44 in
order to face promptly all potential complications. Tables 2–6 pro-
vide information on what health care providers/exercise therapists
should know before, during and after EM and ET.
A full patient medical history and clinical and functional evalua-
tions are prerequisites along with HR monitoring for the detection
and treatment of arrhythmias. Vital signs, self-reported symptom
scores, and VAD function should be monitored, in particular includ-
ing the mean arterial pressure in patients on non-pulsatile VAD sup-
port because hypertension would affect the VAD capacity to pump
blood forward; hypotension and VAD blood flow alterations might
be related to under-filling of the left ventricle secondary to high
pump speed, RV failure, arrhythmias, etc. The VAD team should
be consulted if the mean arterial pressure is below 70mmHg or
higher than 90mmHg, especially when accompanied by VAD alarm
activation. It is also important that the patient is well informed,
reassured and feels safe and secure.
An exercise physiologist or physical therapist should be respon-
sible for securing the cannulas, drivelines and the VAD external
equipment, to prevent damage during mobility.49,50 Once the recip-
ient is confident with transfers from bed, and shows the ability to
carry and to manage the VAD, batteries, and controller,49 EM can
start. The external controller and batteries of recent generations
of VADs are highly portable and do not significantly interfere with
exercise activities, however, some attention should be directed
to avoid abrupt postural changes and body balance issues that
may result from carrying a bag, weighing from 2 to 2.5 kg. Com-
plications such as disconnection from the VAD external power
supply have been described.51,52 Table 2 provides instruction to
reduce the risk of adverse events when exercising VAD patients,
while Table 3 lists the preliminary evaluation and precautions dur-
ing EM.
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Table 2 Instruction to reduce the risk of adverse
events when exercising ventricular assist device
patients
1. Individualised assessment and prescription.
2. Pre-screening with risk stratification.
3. Prolonged graduated warm-up and cool-down.
4. Low-to-moderate intensity exercise training.
5. Avoiding breath holding and Valsalva manoeuvre.
6. Avoiding any trauma, as ventricular assist device recipients
are anticoagulated and (some, not all) treated with
antiplatelet drugs.
7. Adaptation for co-morbidities.
8. Monitoring and supervision.
9. Keeping the feet moving during active recovery, if
appropriate.
10. Observation of patients for 15min post-cessation of
exercise.
Early mobilisation
In every patient, as well as in VAD recipients, EM is defined
as initiating physical exercise within the early illness phase, i.e.
the first step for initiation of exercise therapy, and it consti-
tutes the basic standard modality for ET implementation during
the post-acute phase (Table 4). This preliminary phase is important
but not standardised,53,54 as it is conditioned by the patient’s
status, facilities and timing of referral. According to the patient’s
needs, EM should be adapted, and every day treatment changes
should be considered: supervision from family members and/or
nursing staff is warmly requested, to monitor VAD and clinical
parameters.
This phase is important to rule out contraindications to
exercise49 (Table 5) and should start only when troublesome
accounts after VAD implantation are mostly over.51,52
Early mobilisation prevents the complications of muscle decondi-
tioning and cachexia and, through a broad range of activities, facil-
itates independence.54 EM favours ambulation and includes func-
tional strengthening, muscle endurance and aerobic training, as
for all other HF patients.55–58 Changes in gait are possible as a
result of premature fatigue, appearance of new symptoms or unex-
pected VAD/clinical parameters changes. Possible falls and some
complications such as disconnection from the VAD external power
supply, due to the fact that the driveline has a relatively short
distance from the skin to the controller, have been described.51
The duration of EM is individualised according to progresses and
facilities.19,51
As regards the timing to start, limited available data suggest the
safety of a 6-week interval after implantation,59,60 but in our expert
opinion EM should be considered as soon as the patient’s haemo-
dynamic and clinical status is stable (including surgical wound, skin
integrity maintenance, and pulmonary hygiene), and VAD function-
ing and troubleshooting have been correctly directed.49,51,59 An
algorithm for EM for VAD-supported patients and the transition to
ET is here proposed, based on expert opinion and patient’s apti-
tudes/clinical state (Figure 1). ..
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.. Table 3 Preliminary evaluation and precautions
during early mobilisation in ventricular assist device
recipients
1. Assessment
a. Recent and past medical history, and level of exercise
capacity previous to disease state.
b. Mental status and cognitive ability.
c. Vital signs and risk of cardiovascular instability
(haemodynamic, arrhythmic, clinical).
d. Clinical assessment (persistence of VAD-related and HF
symptoms, even medications have been prescribed).
e. Medications, i.e. need for continuous or intermittent
infusions (inotropic drugs), ventilator settings or oxygen
requirements.
f. Screen range of motion, coordination, balance, strength,
endurance, functional capacity (bed mobility, transfers,
gait, daily living activities).
g. Baseline haemochromocytometric, ionic and renal
functional assessment. We suggest to start exercise when
haemoglobin < 9 g/dL, sodium <130mEq/L, potassium
< 3.8mEq/L and/or creatininemia <1.9mg/dL.
2. Follow sternotomy (6weeks post-surgery screening of
wound) and skin integrity.
3. Patients should always wear a driveline stabilization belt
during exercise.
4. The patient should have his/her travel bag nearby at all times.
It should include a back-up controller, battery clips and spare
batteries.
5. Make early mobilization and exercise sessions comfortable.
Organize an appropriate place to put monitor,
console-controller and batteries (visible for patient and health
care professionals). Discuss this topic with everybody
implicated in the exercise programme.
6. The VAD equipment location should not impede emergency
procedures.
HF, heart failure; VAD, ventricular assist device.
Exercise training
No guidelines describing the specific ET setting, modality and dura-
tion for VAD-supported patients are available, but, as described
in Table 1, only limited evidence of implementation of light exercise
intensities is available. A proper evaluation of symptoms and clin-
ical signs, and functional capacity may help in identifying the most
appropriate settings. Although it is reasonable to assume that
longer ET interventions could improve physical fitness and QoL,
the length and the long-term adherence to these interventions has
not yet been described. Monitoring of exercise sessions is, how-
ever, crucial, at least initially, including supervision of the patient,
clinical adaptation, and VAD functioning.49,59
To optimise exercise workload prescription, a symptom-limited
CPET (or 6MWT) is advisable according to administrative con-
straints and local availability,60,61 in order to aim at a peak workload
below the pre-determined ventilatory anaerobic threshold. If the
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Table 4 How to set up an early mobilisation
programme in ventricular assist device recipients
Consider
1. Positioning.
2. Bed mobility activities.
3. Sitting on edge of bed, in association with exercises.
4. Transfers from bed to stretcher-chair, chair or commode.
5. Gait, with pre-gait activities: weight shifting, stepping in place
and sideways. Gait training is allowed with rolling walker.
6. Breathlessness management and recovery strategies.
7. Attempt to achieve a target of 11 to 14 out of 20 of the Rate
of Perceived Exertion scale.
8. Patient’s native heart rate should not exceed 120 b.p.m.
during exercise, unless under physician’s supervision: heart
rate is not always detectable during early
mobilisation/exercise, and its monitoring depends on device.
Promote
• Low-to-moderate intensity dynamic large muscle group work
(e.g. walking, stationary cycling), or involving upper body
muscles.
• ‘Walk & talk’ approach is suggested.
Limit
• Knee lifts.
• Resistance training (low weight/high repetitions) and with
seated exercise (reduced venous return).
Avoid
• Excessive muscle fatigue.
• Abrupt postural changes and stooped activities.
• Rowing machine.
• Initially, biking due to increased risk of infection near
ventricular assist device percutaneous line exit site.
patient demonstrates a peak VO2 >14mL/kg/min or 6MWT dis-
tance >300m, a more intensive exercise test can be considered.
Figure 2 provides an algorithm for ET in VAD patients.
Additionally, caution is recommended to avoid excessive sweat-
ing and dehydration, as well as rapid changes of posture from supine
to upright positions, which could reduce venous return and neg-
atively impact VAD function40,49,51,59: patients should be urged to
drink regularly.
Each single ET session starts with a warm up phase and
is followed by cool down phase and includes conditioning and
endurance exercises: some exercise activities exert torsion on the
driveline and, therefore, must be avoided.
In summary, based on the available experience in both HF8,9 and
VAD patients,18,20–24 both dynamic and resistance exercise are
indicated: treadmill (increase ramp, not speed), static bike, ham-
string curls in standing position, leg press, bicep curls, core stability,
respiratory muscle training, or arm ergometry. Contraindicated
forms of exercise include running, rowing machine, cross trainer,
abdominals exercises, bilateral arms above the head with weights
or abduction with weights or swimming. ..
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.. Table 5 Criteria for exercise contraindications in
ventricular assist device recipients
1. Symptoms and signs compatible with exercise intolerance
including light headedness, severe intolerable dyspnoea, chest
pain or discomfort, tachycardia and exaggerated blood
pressure response.
2. Symptomatic hypotension (fainting, dizziness, or diaphoresis,
as extreme fatigue or claudication and new onset of
neurological changes).
3. Supine resting heart rate>100 b.p.m.
4. Oxygen saturation< 90% (caveat: oxymetry readings might be
difficult to obtain due to low pulsatility).
5. VAD complications during or after exercise sessions:
a. Alarm activation curves, numbers and alarms should be
displayed on the VAD monitor: trends are useful to track
pump function and patient perfusion. Significant drop in
LVAD flow, or suction alarm are criteria for interrupting
the session.
b. Complex and frequent ventricular arrhythmia on exertion
(caveat: may be asymptomatic).
c. Infection, mainly at the driveline site (infection control
procedures should be followed at all times, e.g. cleaning of
equipment, hand washing, disposal of sharps).
d. Evidence of bleeding as VAD recipients are anticoagulated
or treated with antiplatelet drugs (not all): these drugs are
essential for device working, but they can also enhance
exercise-related bleedings and haematomas.
e. Thrombus (usually evidenced by an increase in the
number of watts/energy necessary for device working).
6. Request of VAD recipient to stop.
7. Increase > 1.8 kg in body mass over the previous 1 to 3 days.
8. Implantable cardioverter-defibrillator intervention
(anti-tachycardia pacing and shocks).
LVAD, left ventricular assist device; VAD, ventricular assist device.
When to stop exercise
The exercise programme should be stopped if:
1. New symptoms or signs are elicited (i.e. fainting, headache,
shortness of breath, chest pain or thoracic pressure, fever,
supraventricular or ventricular arrhythmias).
2. VAD alarms or related problems occur.
3. Unexpected changes are detected in VAD parameters, i.e.
flow, speed and watt operation.
Thus, monitoring of new signs and symptoms and VAD activ-
ity (alarms and related problems) during EM and ET sessions are
needed (Table 5). Of note, arrhythmias may appear during EM
and ET: ventricular arrhythmias are frequent in VAD supported
patients,62 due to a variety of causes.63,64 Sometimes, ventricu-
lar arrhythmias persist over time: arrhythmias do not seem to
be a major concern in recipients, since they provide mostly only
modest haemodynamic deterioration, but they should be carefully
evaluated for, if sustained, they might cause device dysfunction,
through a detrimental effect on the right ventricle, and they might
© 2018 The Authors
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Figure 1 Ventricular assist device recipients and early mobilisation. HF, heart failure; LVAD, left ventricular assist device.
Figure 2 Ventricular assist device (VAD) recipients and exercise training. ET, exercise training.
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Table 6 Summary of clinical parameters to be considered when exercising in ventricular assist device patients
Clinical stability EM Functional capacity ET
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• Unchanged VAD parameters
• Appropriately tackled
VAD-related and not-related
complications
• Duration of EM according to
patient’s condition, VAD
parameters, co-morbidities
and complications
• According to institutional
administrative legacy, but
maximal duration of 6weeks
is suggested
• Preliminary assessment by
CPET or 6MWT
• Duration of ET according to
patient’s condition, VAD
parameters, co-morbidities
and complications
• According to institutional
administrative legacy
• Setting: in- or outpatient
approach
Clinical stability, i.e.
• Stable diuresis
• Stable weight
• No ECG changes
• No complex and/or
sustained ventricular
arrhythmias
• No new sustained
supraventricular arrhythmias
• No changes in mean blood
pressure (< 60mmHg or
>100mmHg)
and no device failure
• No flow < 3 L/min
• No suction events
• No device alarms
and concomitant disease
addressed
• No thrombosis-haemorrhage
• No infection
• No right ventricular failure
• No lung, liver and kidney
failure
• No neurological problems
• Meanwhile management of
acute care factors including
surgical wound, skin integrity
maintenance, pulmonary
hygiene, a range of motion,
cardiovascular, and muscle
strength maintenance should
be addressed with the goal of
free ambulation.
• The cannulas, drivelines and
the VAD external equipment
must be secured to prevent
damage during mobility and
attention should be directed
to abrupt posture changes
and body balance issues that
may result from carrying a
bag, and might lead to
disconnection of VAD.
• CPET: progressive ramp
protocol is recommended,
starting with a warm-up 0W
phase, following a ramp
protocol of 1min steps of
10W/min), aiming subjective
exhaustion or appearance of
criteria for interruption.
• 6MWT: should be
performed indoors, along a
long, flat, straight, enclosed
corridor with a hard surface
that is seldom travelled. The
walking course must be 30m
in length. The turnaround
points should be marked and
a starting line, which marks
the beginning and end of
each 60m lap, should be
marked on the floor. Only
standardized phrases for
encouragement must be
used during the test.
• Light exercise intensities are
recommended, with
monitoring of exercise
sessions.
• If peak VO2 >14mL/kg/min,
or > 300 m are ambulated at
6MWT, a more intensive
exercise session might be
prescribed.
6MWT, 6-minute walking test; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; EM, early mobilisation; ET, exercise training; VAD, ventricular assist device;
VO2, oxygen consumption.
also promote VAD-related symptoms. Before the prescription of
specific anti-arrhythmic drugs, some features should be consid-
ered: optimization of pharmacological therapy (fluid infusion and/or
reduction of daily dose of diuretics), device setting change (if appro-
priate), and postural changes during exercise sessions (i.e. differ-
ent sitting position during bicycle ergometer). Of note, initially ET
should be discontinued. When arrhythmias have been controlled
at rest, exercise can be resumed, albeit at lower frequency and
intensity, and all exercise activities should be strictly supervised and
ECGmonitored. This is a cautionary attitude, not yet supported by
scientific evidence. During exercise, atrial fibrillation might occur:
atrial fibrillation may worsen symptoms and lead to deterioration
of the patient’s clinical status, because of loss of atrioventricular
synchrony and impaired ventricular filling; thus, electrical cardiover-
sion should be considered.62,63 ..
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..
. Different factors should be considered when planning an
exercise programme in VAD recipients,40,49,51,58,59,65 as summarised
in Table 6.
Gaps in knowledge
1. The majority of studies so far have included mainly aerobic
ET, and data focusing on different components of exercise
physiology in VAD recipients are scarce. Thus, the poten-
tial benefits of long-term alternative ET programmes, such
as resistance training, balance training and electrical mus-
cle stimulation, should be still investigated. Prolonged peri-
ods of ET are needed to observe significant effects in
myocardial bioenergetics. This effect might be associated
© 2018 The Authors
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with ventricular unloading and better organ perfusion pro-
vided by the VAD.
2. The vast majority of studies included only LVAD recipients,
which highlights the need to investigate the benefit of ET in
BiVAD patients.
3. Studies comparing exercise capacity pre- and post-VAD
implantation are lacking and might add understanding on the
role of ET in these patients.
4. Based on individual response and adaptation, EM usually
starts early, a few days after the intervention, while ET is
considered to continue indefinitely. However, the optimal
timing and duration of each single ET session are not yet
known.
5. At the beginning, ECG and clinical monitoring are vital: for
how long VAD recipients should be monitored is as yet
unknown. Intuitively, more complicated VAD recipients need
more prolonged supervision.
6. The most effective way to make a patient confident and
feeling safe, and the role of the caregiver have rarely
been addressed. The potential beneficial contribution of
patient education or of a dedicated website needs to be
investigated.66,67
7. The important role of CPET in the exact prescription of ET is
advocated: unfortunately, CPET is poorly implemented, and
the interpretation is unclear in VAD patients. Where evi-
dence is scant, anecdotal actions predominate, and therefore,
for cautionary reasons, low intensity of aerobic training is
here recommended.51,66,67
8. Arterial blood pressure is frequently indeterminable during
ET or EM sessions; this is a limiting factor in monitoring
EM and ET in VAD recipients. If detectable, measurement
of blood pressure before and after exercise is useful, as an
excessive rise in blood pressure may induce adverse events,
including cerebral haemorrhage, stroke and pump thrombo-
sis. Unfortunately, the blood pressure warning level is not
known yet; new symptoms due to exertional maladapta-
tions and alert device-related problems (i.e. excessive work)
should be considered as alarming signs.
9. Ideally, ET may increase the possibility for a VAD implan-
tation episode to lead a bridge-to-recovery situation,
favouring the possibility of weaning, throughout the occur-
rence of metabolic changes in the failing myocardium and
anabolic effects, together with the positive role an adjuvant
pharmacotherapy.68–70 The activation of thyroid hormone
signalling has been suggested to act as a biological driver
for the up-regulation of physiological growth signalling
pathways as indicated by the training-induced activation
of the pro-survival signalling Akt and inactivation of the
anti-hypertrophic JNK in cardiomyocytes, leading to phys-
iological growth even in the failing myocardium. Anabolic
pharmacotherapy (such as 𝛽2-adrenergic receptor agonist
clenbuterol) has been used to facilitate myocardial recovery.
10. VAD unloading therapy and ET might work together for
the improvement of exercise capacity. Vignati et al.32 showed
that LVAD per se might improve exertional profile in recipi-
ents, independently of any ET approach. Only a randomised, ..
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.. non-exercising control group would be able to differentiate
the improvements due to ET from those of device implanta-
tion.
11. The factors involved in determining exercise capacity in the
post-VAD patient need to be investigated in more detail:
it would be an advantage to identify the most important
determinants in an individual patient and focusing therapeutic
strategies on them. For instance, the approach to the sar-
copenic patient may differ from that to the patient whose
main limitation is RV dysfunction.
12. When ET should be started after implantation? Although ET
should be commenced as soon as possible, warning and cau-
tionary criteria are still to be established, and, up-to-now,
personal experience guides the timing of ET in VAD recipi-
ents.
13. Target HR of ET sessions need to be defined, with an
individualised approach being recommended.
Conclusions
Despite LV unloading, impairments persist in VAD patients,
with functional capacity frequently below 50% of predicted peak
VO2. ET may provide additional benefit. Despite some encouraging
small trials, clinical evidence remains limited. Actions should be
taken to expand our understanding fn the potential role of ET
therapy in VAD recipients to promote its wider implementation in
clinical practice.
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